日期 | 股東名稱 | 披露原因 | 買入/賣出涉及 的股份數目 |
每股平均價 | 持有權益的 股份數目 |
佔已發行 股本(%) |
03/08/2023 | UBS Group AG | 1305(L) | 45,921,899(L) | 562,249,510(L) 363,580,867(S) | 14.95 9.67 | |
02/08/2023 | UBS Group AG | 12041(L) | -4,011,014(L) | 563,159,475(L) 364,864,831(S) | 14.97 9.70 | |
28/07/2023 | UBS Group AG | 1305(L) | 64,215,500(L) | 566,190,546(L) 364,884,603(S) | 15.05 9.70 | |
27/07/2023 | UBS Group AG | 1306(L) | 41,099,000(L) | 564,975,451(L) 364,525,808(S) | 15.02 9.69 | |
25/07/2023 | UBS Group AG | 1104(L) | +17,409,071(L) | 571,404,451(L) 362,611,293(S) | 15.19 9.64 | |
17/07/2023 | UBS Group AG | 1306(L) | 14,918,900(L) | 540,321,366(L) 362,538,347(S) | 14.36 9.64 | |
14/07/2023 | UBS Group AG | 1205(L) | -22,461,684(L) | 542,475,866(L) 362,538,383(S) | 14.42 9.64 | |
13/07/2023 | UBS Group AG | 1305(L) | 49,407,700(L) | 568,855,046(L) 365,216,941(S) | 15.12 9.71 | |
12/07/2023 | UBS Group AG | 1306(L) | 36,472,900(L) | 570,192,022(L) 367,413,806(S) | 15.16 9.77 | |
11/07/2023 | UBS Group AG | 1104(L) | +27,274,885(L) | 569,736,451(L) 367,391,174(S) | 15.15 9.77 | |
10/07/2023 | UBS Group AG | 1104(L) | +288,792,900(L) | 694,952,624(L) 367,512,793(S) | 18.47 9.77 | |
10/07/2023 | UBS Group AG | 1104(L) | +136,534,866(L) | 542,694,590(L) 367,512,793(S) | 14.43 9.77 | |
03/07/2023 | UBS Group AG | 1201(L) | -8,253,000(L) | HKD3.318(L) | 409,373,380(L) 372,451,793(S) | 10.88 9.90 |
30/06/2023 | Ginkgo (PTC) Limited | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
30/06/2023 | Nelumbo Investments Limited | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
30/06/2023 | Luye Life Sciences Group Ltd | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
30/06/2023 | Luye Pharma Holdings Ltd. | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
30/06/2023 | LuYe Pharmaceutical International Co., Ltd. | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
30/06/2023 | UBS Group AG | 1201(L) | -68,750,000(L) | HKD3.535(L) | 414,017,118(L) 368,053,174(S) | 11.01 9.78 |
30/06/2023 | 刘殿波 | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
30/06/2023 | Shorea LBG | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
30/06/2023 | LuYe Pharmaceutical Investment Co., Ltd. | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
28/06/2023 | 易方达基金管理有限公司 | 1001(L) | +6,631,000(L) | HKD3.519(L) | 192,746,000(L) | 5.12 |
28/06/2023 | UBS Group AG | 1013(L) 1402(S) | +300,554,500(L) +218,500,000(S) | 477,797,810(L) 365,647,890(S) | 12.70 9.72 | |
03/05/2023 | LuYe Pharmaceutical Investment Co., Ltd. | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Luye Life Sciences Group Ltd | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Nelumbo Investments Limited | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Shorea LBG | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | 刘殿波 | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | 刘殿波 | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | LuYe Pharmaceutical Investment Co., Ltd. | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Luye Pharma Holdings Ltd. | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Ginkgo (PTC) Limited | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Luye Life Sciences Group Ltd | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | LuYe Pharmaceutical International Co., Ltd. | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Ginkgo (PTC) Limited | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Nelumbo Investments Limited | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Luye Pharma Holdings Ltd. | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | LuYe Pharmaceutical International Co., Ltd. | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Shorea LBG | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
1 2 3 4 5 |
備註: | (L) - 長倉:包括 (1) 持有股份;(2) 透過持有、沽出或發行金融合約,有權或有責任購買相關股份。 |
(S) - 短倉:包括 (1) 借入股份;(2) 透過持有、沽出或發行金融合約,有權或有責任沽出相關股份。 | |
(P) - 可供借出的股份 | |
即時報價更新時間為 01/11/2024 17:02 | |
港股即時基本市場行情由香港交易所提供; 香港交易所指定免費發放即時基本市場行情的網站 | |
新聞
股票
期貨期權
權證
ETF
A股
外匯黃金
加密貨幣
基金
MPF